Boditech Med has been focused on protecting inventions in South Korea(KR) with 9 publications in Q3 2023
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 33% filings and 83% grants. The South Korea(KR), European Patent Office (EP)World Intellectual Property Organization (WO), European Patent Office (EP), and United States(US) patent Office are among the top ten patent offices where Boditech Med is filings its patents. Among the top granted patent authorities, Boditech Med has 83% of its grants in South Korea(KR), 17% in United States(US), and 0% in European Patent Office (EP)World Intellectual Property Organization (WO).
Fujifilm could be the strongest competitor for Boditech Med
In terms of grant share, Boditech Med stands in tenth position among its competitors. Fujifilm and Sekisui Chemical secured the top positions according to recent patent publication data.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Patents related to industrial automation and lead Boditech Med’s portfolio
Boditech Med has the highest number of patents in industrial automation followed by, and . For industrial automation, nearly 100% of patents were filed and 100% of patents were granted in Q3 2023.
Laboratory equipment related patents lead Boditech Med portfolio followed by anesthesia and respiratory devices, and
Boditech Med has highest number of patents in laboratory equipment followed by anesthesia and respiratory devices, , and . For laboratory equipment, nearly 50% of patents were filed and 100% of patents were granted in Q3 2023.
For comprehensive analysis of Boditech Med’s filings and grants, buy the databook here.